Skip to main content

Advertisement

SpringerLink
Log in

Rationale and strategies for formulation development of oral fixed dose combination drug products

  • Review
  • Published:
Journal of Pharmaceutical Investigation Aims and scope Submit manuscript

Abstract

The use of fixed dose combination (FDC) drug therapies has been world-widely accepted for long years due to providing better disease treatment with enhanced therapeutic efficacy and safety as well as improved patient compliance and adherence, and reduced cost to patients than single drug therapies. From many different perspectives, the development of FDC products is likely a promising approach to achieving clinical benefits and business advantages in many classes of drugs. The rationale for drug combinations can be well established only when the potential benefits are based on valid therapeutic principles and substantiated by clinical evidences. Herein, how combination products can be rationalized, individually or combinedly, with respect to category of therapeutic benefits, class of pharmacokinetic and pharmacodynamics interactions, and type of combination effects is first discussed. Potential limitations of FDC products are to be minimized through a careful assessment of benefits to risks by selecting rational component drugs and their doses as well as by either taking their efficacious interactions and/or avoiding their non-efficacious interactions. A series of step-wise product development strategies are necessary to attain target product profiles of prospective oral FDC products set based on their intended clinical use. This review gives an overview of strategies for formulation development of oral FDC products to be optimized differently depending upon prior knowledge of single products and designated dosage regimens of the FDC products, along with highlighting the current issues and challenges arising in formulation development and evaluation on the performance of FDC products.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Abdul S, Poddar SS (2004) A flexible technology for modified release of drugs: multi layered tablets. J Control Release 97:393–405

    Article  CAS  PubMed  Google Scholar 

  • Abebe A, Akseli I, Sprockel O, Kottala N, Cuitino AM (2014) Review of bilayer tablet technology. Int J Pharm 461:549–558

    Article  CAS  PubMed  Google Scholar 

  • Akseli I, Dey D, Cetinkaya C (2010) Mechanical property characterization of bilayered tablets using nondestructive air-coupled acoustics. AAPS PharmSciTech 11:90–102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bangalore S, Kamalakkannan G, Parkar S, Messerli FH (2007) Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120:713–719

    Article  PubMed  Google Scholar 

  • Bergmann JF (2008) Review: fixed-dose drug combinations improve medication compliance compared with free-drug regimens. Evid.-Based Med 13:18

    Article  PubMed  Google Scholar 

  • Borghi C, Cicero AFG (2010) Rationale for the use of a fixed-dose combination in the management of hypertension. Clin Drug Investig 30:843–854

    Article  CAS  PubMed  Google Scholar 

  • Burke MD, He X, Cook C, Petrov GA, Long S, Coffin MD (2013) Stability enhancement of drug layered pellets in a fixed dose combination tablet. AAPS PharmSciTech 14:312–320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cahyadi C, Chan L, Colombo P, Heng P (2011) The butterfly effect: a physical phenomenon of hypromellose matrices during dissolution and the factors affecting its occurrence. Int J Pharm 406:31–40

    Article  CAS  PubMed  Google Scholar 

  • Caspi A (2011) Clinical trials, research, and FDA findings. Biotechnol Healthc 8:10–11

    PubMed  PubMed Central  Google Scholar 

  • Chiou WL, Jeong HY, Chung SM, Wu TC (2000) Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res 17:135–140

    Article  CAS  PubMed  Google Scholar 

  • Choi D-H, Jeong S-H (2011) Multi-layered matrix tablets with various tablet designs and release profiles. J Pharm Investig 41:263–272

    Article  CAS  Google Scholar 

  • Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440–446

    Article  CAS  PubMed  Google Scholar 

  • Chrysant SG, Melino M, Karki S, Lee J, Heyrman R (2008) The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 30:587–604

    Article  CAS  PubMed  Google Scholar 

  • Chung M, Calcagni A, Glue P, Bramson C (2006) Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol 46:1030–1037

    Article  CAS  PubMed  Google Scholar 

  • Dashevsky A, Kolter K, Bodmeier R (2004) Compression of pellets coated with various aqueous polymer dispersions. Int J Pharm 279:19–26

    Article  CAS  PubMed  Google Scholar 

  • Desai D, Rao V, Guo H, Li D, Stein D, Hu FY, Kiesnowski C (2012) An active film-coating approach to enhance chemical stability of a potent drug molecule. Pharm Dev Technol 17:227–235

    Article  CAS  PubMed  Google Scholar 

  • Desai D, Wang J, Wen H, Li X, Timmins P (2013) Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol 18:1265–1276

    Article  CAS  PubMed  Google Scholar 

  • Dierickx L, Remon JP, Vervaet C (2013) Co-extrusion as manufacturing technique for multilayer mini-matrices with dual drug release. Eur J Pharm Biopharm 85:1157–1163

    Article  CAS  PubMed  Google Scholar 

  • Dierickx L, Van Snick B, Monteyne T, De Beer T, Remon JP, Vervaet C (2014) Co-extruded solid solutions as immediate release fixed-dose combinations. Eur J Pharm Biopharm 88:502–509

    Article  CAS  PubMed  Google Scholar 

  • Dokoumetzidis A, Macheras P (2006) A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm 321:1–11

    Article  CAS  PubMed  Google Scholar 

  • Dubey R (2012) Bioequivalence challenges in development of fixed-dose combination products: looking beyond reformulation. Expert Opin Drug Deliv 9:325–332

    Article  CAS  PubMed  Google Scholar 

  • Efentakis M, Peponaki C (2008) Formulation study and evaluation of matrix and three-layer tablet sustained drug delivery systems based on Carbopols with isosorbite mononitrate. AAPS PharmSciTech 9:917–923

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • EMA (2006) Guideline on pharmaceutical fixed combination products. European Medicines Agency, London

    Google Scholar 

  • EMA (2015) Guideline on clinical development of fixed combination medicinal products. European Medicines Agency, London

    Google Scholar 

  • Farnier M (2011) Safety review of combination drugs for hyperdemia. Expert Opin Drug Saf 10:363–371

    Article  CAS  PubMed  Google Scholar 

  • FDA (2006) Guidance for industry fixed dose combinations, co-packaged drug products, and single entity versions of previously approved antiretrovirals for the treatment of HIV. Food and Drug Administration (FDA), Rockville

    Google Scholar 

  • FDA (2015) Fixed-combination and co-packaged drugs: applications for approval and combinations of active ingredients under consideration for inclusion in an over-the-counter monograph. Proposed rule, Federal Register, 12/23/2015

  • Foucquier J, Guedj M (2015) Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 3(e00149):1–11

    Google Scholar 

  • Gautam CS, Saha L (2008) Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br J Clin Pharmacol 65:795–796

    Article  PubMed  PubMed Central  Google Scholar 

  • Gradman AH, Basile JN, Carter BL, Bakris GL, Group ASoHW (2010) Combination therapy in hypertension. J Am Soc Hypertens 4:42–50

    Article  CAS  PubMed  Google Scholar 

  • Haidar SH, Davit B, Chen M-L, Conner D, Lee L, Li QH, Lionberger R, Makhlouf F, Patel D, Schuirmann DJ (2008) Bioequivalence approaches for highly variable drugs and drug products. Pharm Res 25:237–241

    Article  CAS  PubMed  Google Scholar 

  • Hainer JW, Sugg J, Vasc J (2007) Metoprolol succinate extended release/hydrochlorothiazide combination tablets. Vasc Health Risk Manag 3:279–288

    CAS  PubMed  PubMed Central  Google Scholar 

  • Heikkinen AT, Baneyx G, Caruso A, Parrott N (2012) Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates—an evaluation and case study using GastroPlus. Eur J Pharm Sci 47:375–386

    Article  CAS  PubMed  Google Scholar 

  • Hiremath PS, Bhonsle SA, Thumma S, Vemulapalli V (2011) Recent patents on oral combination drug delivery and formulations. Recent Pat Drug Deliv Formul 5:52–60

    Article  CAS  PubMed  Google Scholar 

  • Ho L, Muller R, Gordon KC, Kleinebudde P, Pepper M, Rades T, Shen Y, Taday PF, Zeitler JA (2009) Terahertz pulsed imaging as an analytical tool for sustained-release tablet film coating. Eur J Pharm Biopharm 71:117–123

    Article  CAS  PubMed  Google Scholar 

  • Honorio Tda S, Pinto EC, Rocha HV, Esteves VS, dos Santos TC, Castro HC, Rodrigues CR, de Sousa VP, Cabral LM (2013) In vitro-in vivo correlation of efavirenz tablets using GastroPlus(R). AAPS PharmSciTech 14:1244–1254

    Article  PubMed  Google Scholar 

  • Huang L, Li F, Sheng J et al (2014) DrugComboRanker: drug combination discovery based on target network analysis. Bioinformatics 30:i228–i236

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Inman SJ, Briscoe BJ, Pitt KG, Shiu C (2008) Axial tensile fracture of microcrystalline cellulose compacts. Int J Pharm 349:172–179

    Article  CAS  PubMed  Google Scholar 

  • Ito M, Suzuki T, Yada S, Nakagami H, Teramoto H, Yonemochi E, Terada K (2010) Development of a method for nondestructive NIR transmittance spectroscopic analysis of acetaminophen and caffeine anhydrate in intact bilayer tablets. J Pharm Biomed Anal 53:396–402

    Article  CAS  PubMed  Google Scholar 

  • Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8:111–128

    Article  CAS  PubMed  Google Scholar 

  • Just S, Toschkoff G, Funke A, Djuric D, Scharrer G, Khinast J, Knop K, Kleinebudde P (2013) Optimization of the inter-tablet coating uniformity for an active coating process at lab and pilot scale. Int J Pharm 457:1–8

    Article  CAS  PubMed  Google Scholar 

  • Kararli TT (1995) Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16:351–380

    Article  CAS  PubMed  Google Scholar 

  • Kararli TT, Sedo K, Bossart J (2014a) Fixed-dose combination products-A review (Part 1-introduction). Drug Dev Deliv 14(2):32–35

    Google Scholar 

  • Kararli TT, Sedo K, Bossart J (2014b) Fixed-dose combination products-A review (Part 2-analysis). Drug Dev Deliv 14(3):28–32

    Google Scholar 

  • Kararli TT, Sedo K, Bossart J (2014c) Fixed-dose combination products-A review (Part 3-pipeline). Drug Dev Deliv 14(4):36–39

    Google Scholar 

  • Karim MN, Ahmed KR, Bukht MS, Akter J, Chowdhury HA, Hossain S, Anwar N, Selim S, Chowdhury SH, Hossain F, Ali L (2013) Pattern and predictors of dyslipidemia in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Clin Res Rev 7(2):95–100

    Article  Google Scholar 

  • Kim JY, Kim DW, Kuk YM, Park CW, Rhee YS, Oh TO, Weon KY, Park ES (2012) Investigation of an active film coating to prepare new fixed-dose combination tablets for treatment of diabetes. Int J Pharm 427:201–208

    Article  CAS  PubMed  Google Scholar 

  • Koller DM, Hannesschlager G, Leitner M, Khinast JG (2011) Non-destructive analysis of tablet coatings with optical coherence tomography. Eur J Pharm Sci 44:142–148

    Article  CAS  PubMed  Google Scholar 

  • Kottala N, Abebe A, Sprockel O, Akseli I, Nikfar F, Cuitino AM (2012a) Influence of compaction properties and interfacial topography on the performance of bilayer tablets. Int J Pharm 436:171–178

    Article  CAS  PubMed  Google Scholar 

  • Kottala N, Abebe A, Sprockel O, Bergum J, Nikfar F, Cuitino AM (2012b) Evaluation of the performance characteristics of bilayer tablets: Part I. Impact of material properties and process parameters on the strength of bilayer tablets. AAPS PharmSciTech 13:1236–1242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kuentz M (2008) Drug absorption modeling as a tool to define the strategy in clinical formulation development. AAPS J 10:473–479

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kumar V, Prasad B, Singh S (2008) Pharmaceutical issues in the development of a polypill for the treatment of cardiovascular diseases. Drug Discov Today Ther Strateg 5:63–71

    Article  Google Scholar 

  • Kwon KC, Lee C (2016) Analysis of fixed-dose combination products approved by the US food and drug administration, 2010-2015 implications for designing a regulatory shortcut to new drug application. Ther Innov Regul Sci 2168479016663263

  • LaForce C, Gentile DA, Skoner DP (2008) A randomized, double-blind, parallel-group, multicenter, placebo-controlled study of the safety and efficacy of extended-release guaifenesin/pseudoephedrine hydrochloride for symptom relief as an adjunctive therapy to antibiotic treatment of acute respiratory infections. Postgrad Med 120:53–59

    Article  PubMed  Google Scholar 

  • Lai GH, Zhang Z, Sirica AE (2003) Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther 2:265–271

    CAS  PubMed  Google Scholar 

  • Liu Y, Wei Q, Yu G, Gai W, Li Y, Chen X (2014) DCDB 2.0: a major update of the drug combination database. Database bau124:1–6

  • Mandal U, Pal TK (2008) Formulation and in vitro studies of a fixed-dose combination of a bilayer matrix tablet containing metformin HCl as sustained release and glipizide as immediate release. Drug Dev Ind Pharm 34:305–313

    Article  CAS  PubMed  Google Scholar 

  • Marzolini C, Gibbons S, Khoo S, Back D (2016) Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications. J Antimicrob Chemother 71:1755–1758

    Article  CAS  PubMed  Google Scholar 

  • McConnell EL, Macfarlane CB, Basit AW (2009) An observational study on the influence of solvent composition on the architecture of drug-layered pellets. Int J Pharm 380:67–71

    Article  CAS  PubMed  Google Scholar 

  • Migoya EM, Miller JL, Gutierrez M, Zheng W, Johnson-Levonas AO, Liu Q, Matthews CZ, Wagner JA, Gottesdiener KM (2010) Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects. Clin Drug Investig 30:855–866

    Article  CAS  PubMed  Google Scholar 

  • Min JS, Kim D, Park JB et al (2016) Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans. Drug Des Dev Ther 10:2959–2972

    Article  Google Scholar 

  • Mitra A, Wu Y (2012) Challenges and opportunities in achieving bioequivalence for fixed-dose combination products. AAPS J 14:646–655

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nakatani M, Yokoyama K, Sawada T (2014) Bilayer tablet comprising telmisartan and diuretic. US Patents. 8637078

  • Newman J, Grobman WA, Greenland P (2008) Disease prevention in men: a decision analysis and cost-effectiveness model. Prev Cardiol 11:36–412

    Article  PubMed  Google Scholar 

  • Nirmal J, Saisivam S, Peddanna C, Muralidharan S, Godwinkumar S, Nagarajan M (2008) Bilayer tablets of atorvastatin calcium and nicotinic acid: formulation and evaluation. Chem Pharm Bull 56:1455–1458

    Article  CAS  PubMed  Google Scholar 

  • Niwa M, Hiraishi Y, Iwasaki N, Terada K (2013) Quantitative analysis of the layer separation risk in bilayer tablets using terahertz pulsed imaging. Int J Pharm 452:249–256

    Article  CAS  PubMed  Google Scholar 

  • Orloff DG (2005) Fixed combination drugs for cardiovascular disease risk reduction: regulatory approach. Am J Cardiol 96:28K–33K

    Article  PubMed  Google Scholar 

  • Pan F, Chernew ME, Fendrick AM (2008) Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 23:611–614

    Article  PubMed  PubMed Central  Google Scholar 

  • Panchagnula R, Kumar Bajpai A, Agrawal S, Ashokraj Y (2006) Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective study. Pharmazie 61:851–854

    CAS  PubMed  Google Scholar 

  • Park J, Lee S, Kim K, Lee D (2013) Systematic approach for analyzing drug combination by using target-enzyme distance. IBC 5(3):1–7

    Article  Google Scholar 

  • Park HS, Han JH, Jung SH, Jo EJ, Myung CS (2016a) The combination of valsartan and ramipril protects against blood vessel injury and lowers blood pressure. J Pharm Investig 46:265–272

    Article  CAS  Google Scholar 

  • Park JS, Shin JH, Hong TJ et al (2016b) Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong). Drug Des Dev Ther 10:2599–2609

    Article  Google Scholar 

  • Pourkavoos N (2012) Unique risks, benefits, and challenges of developing drug–drug combination products in a pharmaceutical industrial setting. Comb Prod Ther 2:2–31

    Article  Google Scholar 

  • Pritchard JR, Bruno PM, Gilbert LA et al (2013) Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci USA 110:E170–E179

    Article  CAS  PubMed  Google Scholar 

  • Putcharoen O, Do T, Avihingsanon A, Ruxrungtham K (2015) Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS. Drug Des Devel Ther 9:5763–5769

    PubMed  PubMed Central  Google Scholar 

  • Quintavalle U, Voinovich D, Perissutti B, Serdoz F, Grassi G, Dal Col A, Grassi M (2008) Preparation of sustained release co-extrudates by hot-melt extrusion and mathematical modelling of in vitro/in vivo drug release profiles. Eur J Pharm Sci 33:282–293

    Article  CAS  PubMed  Google Scholar 

  • Rege BD, Gawel J, Kou JH (2002) Identification of critical process variables for coating actives onto tablets via statistically designed experiments. Int J Pharm 237:87–94

    Article  CAS  PubMed  Google Scholar 

  • Rosenthal T, Gavras I (2006) Fixed-drug combinations as first-line treatment for hypertension. Prog Cardiovasc Dis 48:416–425

    Article  CAS  PubMed  Google Scholar 

  • Sanz G, Fuster V (2009) Fixed-dose combination therapy and secondarycardiovascular prevention: rationale, selection of drugs and target population. Nat Rev Cardiol 6:101–110. doi:10.1038/ncpcardio1435

    CAS  Google Scholar 

  • Sapte V (2004) Stabilized short-course chemotherapy (SCC) anti-tuberculosis drug compositions. US Patents 200502498

  • Serebruany VL, Malinin AI, Sane DC, Jilma B, Takserman A, Atar D, Hennekens CH (2004) Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol 499:315–324

    Article  CAS  PubMed  Google Scholar 

  • Shah BM, Schafer JJ, Priano J, Squires KE (2013) Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy 33:1107–1116

    Article  CAS  PubMed  Google Scholar 

  • Shiyani B, Gattani S, Surana S (2008) Formulation and evaluation of bi-layer tablet of metoclopramide hydrochloride and ibuprofen. AAPS PharmSciTech 9:818–827

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sica DA (2002) Rationale for fixed-dose combinations in the treatment of hypertension. Drugs 62:443–462

    Article  CAS  PubMed  Google Scholar 

  • Siew A (2015) Fixed-dose combinations. Pharm Technol 39(4):36–39

    Google Scholar 

  • Sperry DC, Thomas SJ, Lobo E (2010) Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug. Mol Pharm 7:1450–1457

    Article  CAS  PubMed  Google Scholar 

  • The HPS2-THRIVE Collaborative Group (2014) Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371:203–212

    Article  Google Scholar 

  • Tiwari RV, Patil H, Repka MA (2016) Contribution of hot-melt extrusion technology to advance drug delivery in the 21st century. Expert Opin Drug Deliv 13:451–464

    Article  CAS  PubMed  Google Scholar 

  • Tobiska S, Kleinebudde P (2003) Coating uniformity and coating efficiency in a Bohle Lab-Coater using oval tablets. Eur J Pharm Biopharm 56:3–9

    Article  CAS  PubMed  Google Scholar 

  • Vaithiyalingam SR, Sayeed VA (2010) Critical factors in manufacturing multi-layer tablets–assessing material attributes, in-process controls, manufacturing process and product performance. Int J Pharm 398:9–13

    Article  CAS  PubMed  Google Scholar 

  • Vynckier AK, Dierickx L, Saerens L, Voorspoels J, Gonnissen Y, De Beer T, Vervaet C, Remon JP (2014a) Hot-melt co-extrusion for the production of fixed-dose combination products with a controlled release ethylcellulose matrix core. Int J Pharm 464:65–74

    Article  CAS  PubMed  Google Scholar 

  • Vynckier AK, Dierickx L, Voorspoels J, Gonnissen Y, Remon JP, Vervaet C (2014b) Hot-melt co-extrusion: requirements, challenges and opportunities for pharmaceutical applications. J Pharm Pharmacol 66:167–179

    Article  CAS  PubMed  Google Scholar 

  • Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ (2009) Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 122:290–300

    Article  PubMed  Google Scholar 

  • WHO (2003) WHO drug information 17(3):143–227

  • WHO (2005) WHO expert committee on specifications for pharmaceutical preparations. WHO Tech Rep Ser No. 929

  • Woodcock J, Griffin JP, Behrman RE (2011) Development of novel combination therapies. N Engl J Med 364:985–987

    Article  CAS  PubMed  Google Scholar 

  • Zeeshan F, Bukhari NI (2010) Development and evaluation of a novel modified-release pellet-based tablet system for the delivery of loratadine and pseudoephedrine hydrochloride as model drugs. AAPS PharmSciTech 11:910–916

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zeeshan F, Peh KK, Tan YT (2009) Exploring the potential of a highly compressible microcrystalline cellulose as novel tabletting excipient in the compaction of extended-release coated pellets containing an extremely water-soluble model drug. AAPS PharmSciTech 10:850–857

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhao S, Nishimura T, Chen Y et al (2013) Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med 5:206ra140

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation funded by the Ministry of Science, ICT & Future Planning (2013M3A9B5075840) and in part by Sunchon National University Research Fund in 2015.

Conflict of interest

All authors (C. Moon and E. Oh) declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon, 57922, Republic of Korea

    Cheol Moon

  2. College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon, Gyeonggi-do, 14662, Republic of Korea

    Euichaul Oh

Authors
  1. Cheol Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Euichaul Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Euichaul Oh.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moon, C., Oh, E. Rationale and strategies for formulation development of oral fixed dose combination drug products. Journal of Pharmaceutical Investigation 46, 615–631 (2016). https://doi.org/10.1007/s40005-016-0286-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40005-016-0286-4

Keywords

Search

Navigation